关于伴有静脉瘤栓 (VTT) 的睾丸生殖细胞肿瘤 (TGCT) 病例的患病率和治疗数据有限。我们的目标是描述 TGCT 与 VTT 的患病率，确定多中心回顾性队列，并确定专家关于该实体最佳管理的意见。使用 IBM Marketscan 数据库，我们确定了接受腹膜后淋巴结清扫术的睾丸癌男性（ RPLND）与同时进行的 VTT 或下腔静脉 (IVC) 肿瘤血栓切除术，以估计 TGCT 中 VTT 的患病率。为了确定多中心回顾性患者队列，我们​​对外科医生进行了调查，并描述了该队列的表现、管理和结果。使用严格标准时，IBM Marketscan 数据库中 TGCT 合并 VTT 的患病率为 0.3% (n = 7/2517)使用宽泛标准时，这一比例为 3.1% (n = 79/2517)。根据我们的调查，来自 10 个中心的 16 名外科医生贡献了 34 名患者的数据。大多数患者（n = 29，85%）患有非精原细胞生殖细胞肿瘤。 93.9%（n = 31）采用手术治疗，其中 63% 采用化疗后肿瘤血栓切除术并进行原发性腔静脉缝合术。 Marketscan 分析仅限于受保个人，不包括临床病理学详细信息，计费代码的使用可能包括患有间质瘤的患者。此外，缺乏对匿名调查的回应限制了数据采集，而且 RedCap 调查没有解决 IVC 阻塞的具体症状，也没有允许对导致 VTT 诊断的影像学进行集中审查。 TGCT 男性中的 VTT 很少见，需要复杂的多学科管理，包括化疗后RPLND时的静脉肿瘤血栓切除术。利用医学数据库，我们估计肿瘤延伸到血管（称为静脉肿瘤血栓，VTT）的睾丸癌病例的频率仅为0.3-3.1%。我们对有这种情况经验的外科医生进行了一项调查。我们的结果表明，尽管睾丸癌对化疗反应良好，但 VTT 反应较差，对于这种罕见的情况需要进行复杂的手术。版权所有 © 2024 欧洲泌尿外科协会。由 Elsevier B.V. 出版。保留所有权利。

There are limited data on the prevalence and management of testicular germ cell tumor (TGCT) cases presenting with venous tumor thrombus (VTT). Our objectives were to describe the prevalence of TGCT with VTT, to identify a multicenter retrospective cohort, and to ascertain expert opinion regarding optimal management of this entity.Using the IBM Marketscan database, we identified men with testicular cancer who underwent retroperitoneal lymph node dissection (RPLND) with concurrent VTT or inferior vena cava (IVC) tumor thrombectomy to estimate the prevalence of VTT in TGCT. To identify a multicenter retrospective cohort of patients, we surveyed surgeons and described the presentation, management, and outcomes for the cohort.The prevalence of TGCT with VTT in the IBM Marketscan database was 0.3% (n = 7/2517) when using stringent criteria and 3.1% (n = 79/2517) when using broad criteria. In response to our survey, 16 surgeons from ten centers contributed data for 34 patients. Most patients (n = 29, 85%) presented with nonseminomatous germ cell tumor. Surgical management was used for 93.9% (n = 31), including postchemotherapy tumor thrombectomy with primary cavorrhaphy in 63%. The Marketscan analysis was limited to insured individuals and did not include clinicopathological details, and use of billing codes may have included patients with stromal tumors. In addition, lack of responses to the anonymous survey limited data capture, and the RedCap survey did not address symptoms specific to IVC obstruction or allow central review of the imaging leading to VTT diagnosis.VTT among males with TGCT is rare and requires complex multidisciplinary management, including venous tumor thrombectomy at the time of postchemotherapy RPLND.Using a medical database, we estimated that the frequency of testicular cancer cases in which the tumor extends into a blood vessel (called venous tumor thrombus, VTT) is just 0.3-3.1%. We carried out a survey of surgeons with experience of this condition. Our results indicate that although testicular cancers respond well to chemotherapy, VTT is less responsive and complex surgery is necessary for this rare condition.Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.